Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

EHU005501

Sigma-Aldrich

MISSION® esiRNA

targeting human MAP3K21

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CGTCCATCGTTTGCCTTAATTCTCGAACAGTTGACTGCTATTGAAGGGGCAGTGATGACTGAGATGCCTCAAGAATCTTTTCATTCCATGCAAGATGACTGGAAACTAGAAATTCAACAAATGTTTGATGAGTTGAGAACAAAGGAAAAGGAGCTGCGATCCCGGGAAGAGGAGCTGACTCGGGCGGCTCTGCAGCAGAAGTCTCAGGAGGAGCTGCTAAAGCGGCGTGAGCAGCAGCTGGCAGAGCGCGAGATCGACGTGCTGGAGCGGGAACTTAACATTCTGATATTCCAGCTAAACCAGGAGAAGCCCAAGGTAAAGAAGAGGAAGGGCAAGTTTAAGAGAAGTCGTTTAAAGCTCAAAGATGGACATCGAATCAGTTTACCTTCAGATTTCCAGCACAAGATAACCGTGCAGGCCTCTCCCAACTTGGACAAA

Ensembl | human accession no.

ENSG00000143674

NCBI accession no.

NM_032435

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... MAP3K21(84451) , MAP3K19(84451)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stefen A Boehme et al.
PloS one, 11(5), e0154874-e0154874 (2016-05-06)
Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating disease for which two medications, pirfenidone and nintedanib, have only recently been approved for treatment. The cytokine TGF-β has been shown to be a central mediator in the disease process. We investigated
Stefen A Boehme et al.
PloS one, 11(12), e0167169-e0167169 (2016-12-10)
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and lung inflammation resulting in a progressive decline in lung function whose principle cause is cigarette smoke. MAP3K19 is a novel kinase expressed predominantly by alveolar and interstitial macrophages

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service